It has been announced that Innovate UK is to provide £1m of funding for a project to apply machine-learning techniques to drug discovery.
The funding goes to a recently announced collaboration between the not-for-profit Medicines Discovery Catapult, software company Optibrium, and deep-learning firm Intellegens, a spin-out from the University of Cambridge.
The aim of the project is to use advanced machine-learning techniques to predict the properties of novel drug candidates. Better understanding of the action, pharmacodynamics, and potential off-target effects would allow better screening of candidate molecules, reducing the failure rates in pre-clinical testing. This offers the potential of speeding up drug discovery, and reducing the costs involved.